Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

IT leads Indian stock markets
Mon, 14 Nov 09:30 am

Asian stock markets have opened the day on a firm note. Stock market in Hong Kong (up 2.3%), South Korea (up 2.0%), Singapore (up 1.7%), China (up 1.6%), Japan (up 1.1%) and Indonesia (up 1.1%) is in the green. The Indian stock market have opened the day on a firm note. Stocks in the IT and Realty space are leading the gains.

The BSE-Sensex is trading up by 170 points (1%) and the NSE-Nifty is up by around 53 points (1.1%). BSE Midcap and BSE Small cap stocks are trading in the green, with the BSE Mid Cap and BSE Small Cap indices up by 0.6% and 0.5% respectively. The rupee is trading at 49.99 to the US dollar.

Auto stocks have opened the day on a firm note with Maruti and Mahindra & Mahindra in the green. There is a possibility that Mahindra and Ssangyong car models will be kept for sale under the same roof for various international markets. Ssangyong is a Korean carmaker acquired by Mahindra. The strategy is to boost both the brands and help expand their footprints in markets like Europe, Africa, Latin America and South-East Asia. The idea of having common dealerships follows the target of increasing the volumes and revenues for Mahindra. The target set by the company is to increase the global revenues by four times to 20% from currently 5% by 2016. The company said that the joint dealerships will take a few months to start, however there will be a clear demarcation of the two brands.

Pharma stocks have opened the day on a firm note with Sun Pharma and Cipla leading the gains while Pfizer and Wyeth is in the red. Glenmark Pharma has declared its results for the second quarter of 2011-12 (2QFY12). The company has reported a 45.8% YoY growth in net sales and 35.2% YoY de-growth in net profits. Net sales grew by 45.8% YoY led by growth in specialty business which includes revenue from out-licensing revenues. The speciality business (contributes ~60% to sales) grew by 67.3% on back of out-licensing revenues and strong growth from Latin America and ROW markets. Operating margins (EBITDA) rise 190 bps (1.9%) to 21.4% with decrease in raw material and employee costs. However, other expenditure increased substantially. Net profits de-grow by 35.2% YoY. Growth in net profits was lower than that of sales due to exceptional losses incurred.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "IT leads Indian stock markets". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.